Rezolute, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Nevan Charles Elam
- Full Time Employees
- 58
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 275 Shoreline Drive Redwood City CA United States of America 94065
- IPO Date
- Jan 14, 2013
- CIK
- 0001509261
- Website
- rezolutebio.com
- Similar Companies
- Business
- Rezolute, Inc. (Nasdaq: RZLT) is a late-stage biopharmaceutical company developing transformative therapies for rare endocrine diseases, including congenital and severe insulin-resistant hyperinsulinemic hypoglycemia (HIHH) and congenital hyperinsulinism (CHI). The company focuses on its lead investigational product candidate, bezdutide (RZ358), a novel human monoclonal antibody that binds to an allosteric site on the insulin receptor to reduce insulin signaling and lower blood glucose levels; it is currently in Phase 3 clinical development for both congenital and tumor HIHH under the tradename RZ358, with topline data expected in the first half of 2025. Additional pipeline programs include RZ402, an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema, and earlier-stage assets targeting other endocrine disorders. Rezolute was founded in 2010 and is headquartered in Redwood City, California, with operations primarily in the United States. In the past two years, the company completed enrollment in its Phase 3 RISE-HIHH study for bezdutide in November 2024, announced positive Phase 2b data for tumor HIHH in September 2024, secured a $15 million strategic investment from a leading healthcare investor in Q3 2025 to support Phase 3 advancement, and expanded its manufacturing partnerships for commercial-scale production ahead of potential regulatory filings in 2026. Rezolute targets pediatric and adult patients with rare metabolic diseases, serving global markets with an emphasis on North America and Europe through collaborations with specialized clinical networks.
Company News
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Rezolute, Inc. (NASDAQ:RZLT) Stock Now Rated “Moderate Buy” by Sell-Side Analysts
Rezolute (NASDAQ:RZLT) Stock Sees Unusually High Call Option Buying
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
Rezolute, Inc. (NASDAQ:RZLT) Receives $9.38 Average Price Target from Analysts
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
Rezolute to Participate in Upcoming Investor Conferences
Rezolute, Inc. $RZLT Shares Sold by Bank of America Corp DE
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
Rezolute to Participate in Upcoming Investor Conferences
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
Rezolute, Inc. Investigated by the Portnoy Law Firm
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting